An observational study in Chronic Rhinosinusitis With Nasal Polyposis, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 81 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Regeneron Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Rhinosinusitis with a site in United States — 11 open to participants now, 18 under way, 7 of them phase 3. Rhinosinusitis · United States.
Among the 71 studies in Rhinosinusitis with a site in United States, this one is the 3rd largest by enrollment of the 16 observational ones that give a count, is one of 5 that started in 2021, is one of 16 observational ones, reaches primary completion later than 7 of the 17 other live ones, and was the 48th registered.
252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.
Browse Rhinosinusitis studies →11 of the 71 studies in Rhinosinusitis with a site in United States are open now. Recruiting first, the newest first:
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Airiver Medical, Inc. · Sites in United States
Ages 18+
Optinose US Inc. · Sites in United States
Ages 12–17
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
The European Forum for Research and Education in Allergy and Airway Diseases · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 15 · Phase 4 12
First in 2003; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 717 is above the median of 123 across 62 observational studies indexed under Rhinosinusitis.
Median enrollment 59 across the 55 interventional studies, 70 across the 16 observational. Of the 46 that completed or were terminated, 24 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 71 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Rhinosinusitis — fewer than ten, so there is no comparison to draw.
10 of the studies in Rhinosinusitis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706817Phase 3AstraZenecaA Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | 2027-01-13 |
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT06567821Phase 3Cedars-Sinai Medical CenterUsing Navigation to Improve Accuracy of Maxillary Balloon Sinusotomy | 2027-10-01 |
| NCT02038166University of Alabama at BirminghamNasal Potential Difference (NPD) Protocol in Chronic Rhinosinusitis | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 71 studies in Rhinosinusitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are:
The secondary objectives of the study are:
Patients who are initiating treatment with DUPIXENT® for CRSwNP according to the country-specific prescribing information.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
Also known as: dupilumab, REGN668, SAR231893
Baseline Patient Characteristics
Demographics includes but is not limited to gender, age, ethnicity, height, weight, BMI, education, current employment status, physician information.
Time frame: Baseline up to 3 years
Baseline Disease Characteristics
Medical History includes but is not limited to history of CRSwNP, comorbid conditions, age at CRSwNP diagnosis, and baseline measurements of effectiveness variables.
Time frame: Baseline up to 3 years
DUPIXENT® Treatment Characteristics
Including but not limited to: usage, dosage, adherence, interruption, place (home or clinic) and frequency of administration
Time frame: Baseline up to 3 years
CRSwNP Treatment Characteristics
Including but not limited to: usage, dosage, adherence, duration and frequency
Time frame: Baseline up to 3 years
Incidence and severity of adverse events (AEs)
Time frame: Baseline up to 3 years
Participant Assessment: Total symptom score (TSS), including sub-scores (nasal congestion [NC] and loss of smell [LOS])
The TSS is a composite score (ranging between 0 and 9) and consisting of the sum of the following symptoms assessed daily: nasal congestion/obstruction, decreased/loss of sense of smell, rhinorrhea (average of anterior/posterior nasal discharge). Higher scores indicate greater symptom burden.
Time frame: Baseline up to 3 years
Physician Assessment: Change in University of Pennsylvania Smell Identification Test (UPSIT) score
The UPSIT (UPSIT 40-odorant test) is a rapid and easy-to-administer method to quantitatively assess human olfactory function.
Time frame: Baseline up to 3 years
Physician Assessment: CT-Lund-Mackay Score
The LMK system is scoring based on CT imaging of the sinuses with points given for degree of opacification: 0 = no opacification, 1 = partial opacification, 2 = total opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side. The ostiomeatal complex is graded as 0 = not occluded, or 2 = occluded. The sum of these derives a maximum score of 12 per side and 24 in total.
Time frame: Baseline up to 3 years
Physician Assessment: Nasal Peak Inspiratory Flow (PNIF)
Nasal peak inspiratory flow (NPIF) is a measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute.
Time frame: Baseline up to 3 years
Physician Assessment: - Forced Expiratory Volume in 1 second (FEV1)
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled in the first second of a forced exhalation
Time frame: Baseline up to 3 years
Physician Assessment: Fractional exhaled Nitric Oxide (FeNO)
FeNO (Fractional exhaled Nitric Oxiide) is analyzed using a respiratory flow rate of 50 mL/second and reported in ppb.
Time frame: Baseline up to 3 Years
Participant Assessment: Asthma Control Questionnaire, 6-item (ACQ-6)
The ACQ-6 assesses asthma control with scores ranging from 0 (fully controlled; 6=severely uncontrolled).
Time frame: Baseline up to 3 Years
Participant Assessment: Mini Asthma Quality of Life Questionnaire (MiniAQLQ)
The MiniAQLQ is assesses the impact of asthma on health-related quality of life with scores ranging from 1 (maximum impairment) to 7 (no impairment).
Time frame: Baseline up to 3 Years
Participant Assessment: Allergic Rhinitis (AR) using AR Visual Analog Scale (VAS)
The AR-VAS assesses severity of rhinosinusitis symptoms on a 0 (not troublesome) to 10 (worst thinkable troublesome) scale.
Time frame: Baseline up to 3 Years
Participant Assessment: Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ)
The MiniRQLQ is an abbreviated version of the RQLQ(S)+12 which assesses health-related quality of life associated with perennial or seasonal allergic rhinitis with scores ranging from 0 (not troubled) to 6 (extremely troubled).
Time frame: Baseline up to 3 Years
Participant Assessment: Sino-Nasal Outcome Test (SNOT-22)
The SNOT-22 assesses the impact of chronic rhinosinusitis on health-related quality of life with scores ranging from 0 to 110; lower scores representing better health related quality of life.
Time frame: Baseline up to 3 Years
Participant Assessment: Patient Oriented Eczema Measure (POEM)
The POEM assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping with scores ranging from 0 to 28; higher scores indicate greater symptom burden.
Time frame: Baseline up to 3 Years
Participant Assessment: Work Productivity and Activity Impairment Questionnaire for asthma (WPAI-CRSwNP)
The WPAI-CRSwNP measures impairments in work and activities associated with CRSwNP. Scores are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: Baseline up to 3 Years
Physician Assessment: Changes of Healthcare Utilization
Resource use collected from medical, hospital, and pharmacy records
Time frame: Baseline up to 3 years
Participant Assessment: Short Form 12
The SF-12 assesses physical functioning, social functioning, role limitations due to physical problems, role limitations due to emotional problems, mental health, energy/vitality, pain, and general health perception with scores ranging from 0 to 100; lower scores represent greater quality of life impairment.
Time frame: Baseline up to 3 years
Participant Assessment: European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
The EQ 5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and the EQ-VAS records the respondent's self rated health on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline up to 3 years
Participant Assessment: Global Impression for Symptom Severity, Treatment Satisfaction (Global Patient Assessment)
The Global Patient Assessment is a 2-component questionnaire on symptom severity over the past week and the patient's overall satisfaction with their CRSwNP treatment.
Time frame: Baseline up to 3 years
Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment)
The Global Physician Assessment is a 1-item question asking physicians to rate the severity of their patient's CRSwNP.
Time frame: Baseline up to 3 years
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Started Aug 2021 (actual). Primary completion is estimated for Mar 2027, 67 months after the start.
Of 22 observational studies under Rhinosinusitis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 71. This study's planned 67 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.